Citations

Clear

163 citation(s) found for "Sharp, H L".

An ethics framework for consolidating and prioritizing COVID-19 clinical trials
Meyer, Michelle N. , Gelinas, Luke , Hull, Sara Chandros , Magnus, David , Mohapatra, Seema , Sharp, Richard R. , Spector‐Bagdady, Kayte , Wilfond, Benjamin S. , Sugarman, Jeremy , Lynch, Holly Fernandez , Sharp, Richard R , Bierer, Barbara E. , Joffe, Steven

Mayo Clinic

Clinical Trials | February 10, 2021 | Volume: 18 | Issue: 2 | Pages: 226-233

10.1177/1740774520988669 | PMID 33530721 Get It

Given the dearth of established safe and effective interventions to respond to COVID-19, there is an urgent ethical imperative to conduct meaningful clinical research. The good news is that interventions to be tested are not in short supply. Unfortunately, the human and material resources needed to conduct these trials are finite. It is essential that trials be robust and meet enrollment targets and that lower-quality studies not be permitted to displace higher-quality studies, delaying answers to critical questions. Yet, with few exceptions, existing research review bodies and processes are not designed to ensure these conditions are satisfied. To meet this challenge, we offer guidance for research institutions about how to ethically consolidate and prioritize COVID-19 clinical trials, while recognizing that consolidation and prioritization should also take place upstream (among manufacturers and funders) and at a higher level (e.g. nationally). In our proposed three-stage process, trials must first meet threshold criteria. Those that do are evaluated in a second stage to determine whether the institution has sufficient capacity to support all proposed trials. If it does not, the third stage entails evaluating studies against two additional sets of comparative prioritization criteria: those specific to the study and those that aim to advance diversification of an institution’s research portfolio. To implement these criteria fairly, we propose that research institutions form COVID-19 research prioritization committees. We briefly discuss some important attributes of these committees, drawing on the authors’ experiences at our respective institutions. Although we focus on clinical trials of COVID-19 therapeutics, our guidance should prove useful for other kinds of COVID-19 research, as well as non-pandemic research, which can raise similar challenges due to the scarcity of research resources.
The Value of Patient Perspectives in an Ethical Analysis of Recruitment and Consent for Intracranial Electrophysiology Research
Richardson, Jordan , Balzekas, Irena , Richardson, Jordan P , Lundstrom, Brian Nils, Sharp, Richard R , Lundstrom, Brian N. , Worrell, Gregory A. , Sharp, Richard R.

Mayo Clinic

AJOB Neuroscience | February 3, 2021 | Volume: 12 | Issue: 1 | Pages: 75-77

10.1080/21507740.2020.1866114 | PMID 33528326 Get It

Patients’ values and other decisional factors regarding treatment of hypercalcemia of malignancy: A Systematic Review Protocol
Bassatne, Aya , Rahme, Maya , Piggott, Thomas , Hneiny, Layal , Fuleihan, Ghada El‐Hajj , El-Hajj Fuleihan, Ghada , Piggott, Thomas , Murad, M. Hassan

Mayo Clinic

No container title available | January 22, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-64830/v2 Get It

Abstract Background: Hypercalcemia of malignancy is the second most common cause of hypercalcemia and is associated with significant morbidity and mortality. Several treatment options are available including pharmacological therapy with bisphosphonates, denosumab, glucocorticoids, and calcimimetics, as well as conventional therapy with hydration and possibly calcitonin. While guidelines have previously considered treatment effects, no guideline has yet considered a range of contextual factors impacting recommendations for the management. Objective: The aim of this study is to summarize the available evidence on important decisional factors for the development of guidelines for the treatment of hypercalcemia of malignancy. These include patient’s values and preferences, cost, acceptability, feasibility, and equity. Methods/Design: This is a systematic review of observational studies, case series, trials, reviews and qualitative studies involving treatment of adult patients with hypercalcemia of malignancy. We developed and executed two independent search strategies using five databases: Pubmed, Medline (OVID), Embase.com, CINAHL (EBSCO) and Cochrane, and reviewed their combined output. Two reviewers screened titles and abstracts and full texts and will implement data abstraction from relevant studies independently and in duplicate. The outcomes of interest are the decisional factors that influence drug selection, with possible subgroup analyses by drug class or etiology of hypercalcemia of malignancy. We will present the data collected in a narrative and thematic approach. Discussion: This systematic review will identify important treatment decisional factors, and will assist guidelines panels, physicians and patients to decide on therapeutic options based on the current evidence.
Returning negative results from large‐scale genomic screening: Experiences from the eMERGE III network
Finn, Kelsey Stuttgen , Aufox, Sharon , Bland, Harris T. , Halverson, Colin , Hebbring, Scott J. , Hoell, Christin , Jarvik, Gail P. , Leppig, Kathleen A. , Myers, Melanie F. , Prows, Cynthia A. , Rasouly, Hila Milo , Weisner, Georgia, Williams, Janet L. , Wynn, Julia , Smith, Maureen E. , Sharp, Richard R. , Halverson, Colin , Kullo, Iftikhar J , Myers, Melanie F , Sharp, Richard R , Bland, Sarah T , Milo Rasouly, Hila , Jarvik, Gail P , Hoell, Christin , Stuttgen, Kelsey , Lynch, John , Chung, Wendy K. , Holm, Ingrid A. , Kullo, Iftikhar J. , Singh, Rajbir

Mayo Clinic

American Journal of Medical Genetics Part A | December 8, 2020 | Volume: 185 | Issue: 2 | Pages: 508-516

10.1002/ajmg.a.62002 | PMID 36046768 Get It

AbstractPopulation‐based genomic screening has the potential to improve health outcomes by identifying genetic causes of disease before they occur. While much attention has been paid to supporting the needs of the small percentage of patients who will receive a life‐altering positive genomic screening result that requires medical attention, little attention has been given to the communication of negative screening results. As there are currently no best practices for returning negative genomic screening results, we drew on experiences across the electronic medical records and genomics (eMERGE) III Network to highlight the diversity of reporting methods employed, challenges encountered in reporting negative test results, and “lessons learned” across institutions. A 60‐item survey that consisted of both multiple choice and open‐ended questions was created to gather data across institutions. Even though institutions independently developed procedures for reporting negative results, and had very different study populations, we identified several similarities of approach, including but not limited to: returning results by mail, placing results in the electronic health record via an automated process, reporting results to participants' primary care provider, and providing genetic counseling to interested patients at no cost. Differences in procedures for reporting negative results included: differences in terminology used to describe negative results, definitions of negative results, guidance regarding the meaning of negative results for participants and their family members, and recommendations for clinical follow up. Our findings highlight emerging practices for reporting negative genomic screening results and highlight the need to create patient education and clinical support tools for reporting negative screening results.
Popular MRI de‐facing software does not sufficiently protect participants from re‐identification via face recognition
Therneau, Terry M. , Gunter, Jeffrey L. , Spychalla, Anthony J., Petersen, Ronald C. , Schwarz, Christopher G. , Kremers, Walter K. , Sharp, Richard R. , Vemuri, Prashanthi , Arani, Arvin , Kantarci, Kejal , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S4 | Pages: No page available

10.1002/alz.045157 Get It

AbstractBackgroundData shared for research use must be de‐identified to protect participant confidentiality. A recent study has shown that face imagery from brain imaging studies could be used to re‐identify anonymous participants via automatic face recognition, linking them with all study‐collected protected health information. Here we measure how well existing software for removing MRI face imagery protects against this privacy threat.MethodWe recruited 153 participants with existing 3D FLAIR MRI and photographed their face from 5 varying angles. We used surf_ice to reconstruct each participant’s face from their MRI and tested whether free, publicly‐available face recognition software (Microsoft Azure) could match their photos to their correct MRI. We tested two existing programs for removing face voxels in MRI: mri_deface (FreeSurfer) and pydeface (python package), and one in‐house implementation. We observed that existing methods often left participants’ eyes intact while removing most of their nose/mouth/chin. This prevented Azure from detecting the reconstructions as faces, therefore preventing its attempt of face recognition. We hypothesized that the retained eye imagery alone could be sufficient for face recognition, if a face were detected. Therefore, we also reconstructed each de‐faced MRI after applying novel pre‐processing that replaced any removed/missing face voxels with those from our population‐average template, e.g. replacing missing noses/mouths/chins with population‐average noses/mouths/chins, before testing face recognition.ResultsWithout any MRI de‐facing, Microsoft Azure correctly matched 78% of participants’ photos to their MRI. After mri_deface and pydeface, 8% and 6% were still identified, respectively. After preprocessing the de‐faced MRI to replace missing areas with those from a population‐average template prior to face reconstruction, the face imagery remaining in the de‐faced images was enough to allow re‐identification of 23% and 20% of participants, respectively. With an in‐house face removal implementation that removes the whole face from every image, 0% of faces were re‐identified from the standard reconstructions, and 5% were identified from the “missing‐parts‐replacement” reconstructions.ConclusionsEven after applying popular MRI de‐facing software, Microsoft Azure face recognition automatically re‐identified up to 23% of participants. Better de‐facing software is needed to remove more of the face more reliably, without affecting brain measurements from de‐faced images.
Total, Bioavailable, and Free 25(OH)D Relationship with Indices of Bone Health in Elderly: A Randomized Controlled Trial
Sabeh, Malak El , Rahme, Maya , Halaby, Georges, Vanderschueren, Dirk , Bouillon, Roger , Fuleihan, Ghada El‐Hajj , El-Hajj Fuleihan, Ghada , Ghanem, Paola , Al‐Shaar, Laila , Baddoura, Rafic , Singh, Ravinder J.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 6, 2020 | Volume: 106 | Issue: 2 | Pages: e990-e1001

10.1210/clinem/dgaa780 | PMID 33280041 Get It

Abstract Context Questions regarding the superiority of free and bioavailable 25-hydroxyvitamin D [25(OH)D] in predicting health outcomes remain unresolved. Objective This study investigates the impact of vitamin D variables—total, bioavailable, or free 25(OH)D—on indices of bone and mineral metabolism, at baseline and in response to 2 vitamin D doses. Design Our objectives are implemented as exploratory analyses on data collected in a 1-year, double-blind, randomized controlled trial completed in July 2014. Setting Participants were recruited from 3 major hospitals in an ambulatory setting. Participants Participants were >65 years of age, overweight, and had a baseline serum 25(OH)D between 10 and 30 ng/mL. A total of 221 participants completed the study. Intervention Subjects were randomized to receive calcium and oral vitamin D3 (600 IU/day or 3750 IU/day) supplementation. Results Participants who received the higher vitamin D dose had levels that were 1.3- to 1.4-fold higher than those taking the lower dose, for all variables (P value < 0.001). Serum values of bioavailable and free 25(OH)D were associated with total 25(OH)D, with r values of 0.942 and 0.943, respectively (P value < 0.001). Parathyroid hormone (PTH) was negatively associated with all vitamin D variables, with correlation coefficients ranging from −0.22 to −0.25, while calcium and bone turnover markers (carboxy-terminal collagen crosslinks and osteocalcin) did not. Only total 25(OH)D had a positive relationship with % change bone mineral density (BMD) at the femoral neck at 12 months, while only free and bioavailable 25(OH) had a positive relationship with % change total body BMD at 12 months. Conclusion Calculated free and bioavailable 25(OH)D do not appear to be superior to total 25(OH)D in predicting indices of bone health in an elderly population.
“They’re Not Going to Do Nothing for Me”: Research Participants’ Attitudes towards Elective Genetic Counseling
Sutton, Erica J., Beck, Annika T., Gamm, Kylie O., Sharp, Richard R. , Sharp, Richard R , McCormick, Jennifer Blair , Kullo, Iftikhar J.

Mayo Clinic

Journal of Personalized Medicine | September 25, 2020 | Volume: 10 | Issue: 4 | Pages: 143

10.3390/jpm10040143 | PMID 32987879 Get It

As applications of genomic sequencing have expanded, offering genetic counseling support to all patients is arguably no longer practical. Additionally, whether individuals desire and value genetic counseling services for genomic screening is unclear. We offered elective genetic counseling to 5110 individuals prior to undergoing sequencing and 2310 participants who received neutral results to assess demand. A total of 0.2% of the study participants accessed genetic counseling services prior to sequencing, and 0.3% reached out after receiving neutral results. We later conducted 50 interviews with participants to understand why they did not access these services. Many interviewees did not recall the availability of genetic counseling and were unfamiliar with the profession. Interviewees described not needing counseling before sequencing because they understood the study and felt that they could cope with any result. Counseling was considered equally unnecessary after learning neutral results. Although the participants had questions about their results, they did not feel that speaking with a genetic counselor would be helpful. Genomic screening efforts that employ opt-in models of genetic counseling may need to clarify the potential value of genetic counseling support from the outset and feature genetic counseling services more prominently in program materials.
Full-thickness resection device (FTRD) for treatment of upper gastrointestinal tract lesions: the first international experience
Khashab, Mouen A., Sharaiha, Reem Z. , Hajifathalian, Kaveh , Ichkhanian, Yervant , Dawod, Qais, Schmidt, Arthur , Glaser, Nicholas, Vosoughi, Kia , Templeton, Adam W. , Samarasena, Jason , Chehade, Nabil El Hage , Lee, John G., Chang, Kenneth J. , Mizrahi, Meir, Barawi, Mohammed, Irani, Shayan , Friedland, Shai , Korc, Paul , Aadam, A. Aziz , Kowalski, Thomas E., Smallfield, George , Ginsberg, Gregory G. , Kumta, Nikhil A. , Tang, Shou-jiang, Naga, Yehia M. , Amateau, Stuart K. , Kasmin, Franklin, Goetz, Martin , Seewald, Stefan , Kumbhari, Vivek , Ngamruengphong, Saowanee , Mahdev, Srihari, Mukewar, Saurabh , Sampath, Kartik, Carr‐Locke, David L. , Khashab, Mouen A. , Meining, Alexander , Diehl, David L. , Grimm, Ian S. , James, Theodore , Al‐Haddad, Mohammad , Fukami, Norio , Lajin, Michael

Mayo Clinic

Endoscopy International Open | September 22, 2020 | Volume: 08 | Issue: 10 | Pages: E1291-E1301

10.1055/a-1216-1439 | PMID 33015330 Get It

Abstract Background and study aims The Full-Thickness Resection Device (FTRD) provides a novel treatment option for lesions not amenable to conventional endoscopic resection techniques. There are limited data on the efficacy and safety of FTRD for resection of upper gastrointestinal tract (GIT) lesions. Patients and methods This was an international multicenter retrospective study, including patients who had an endoscopic resection of an upper GIT lesion using the FTRD between January 2017 and February 2019. Results Fifty-six patients from 13 centers were included. The most common lesions were mesenchymal neoplasms (n = 23, 41 %), adenomas (n = 7, 13 %), and hamartomas (n = 6, 11 %). Eighty-four percent of lesions were located in the stomach, and 14 % in the duodenum. The average size of lesions was 14 mm (range 3 to 33 mm). Deployment of the FTRD was technically successful in 93 % of patients (n = 52) leading to complete and partial resection in 43 (77 %) and 9 (16 %) patients, respectively. Overall, the FTRD led to negative histological margins (R0 resection) in 38 (68 %) of patients. A total of 12 (21 %) mild or moderate adverse events (AEs) were reported. Follow-up endoscopy was performed in 31 patients (55 %), on average 88 days after the procedure (IQR 68–138 days). Of these, 30 patients (97 %) did not have any residual or recurrent lesion on endoscopic examination and biopsy, with residual adenoma in one patient (3 %). Conclusions Our results suggest a high technical success rate and an acceptable histologically complete resection rate, with a low risk of AEs and early recurrence for FTRD resection of upper GIT lesions.
MOG-IgG1 and co-existence of neuronal autoantibodies
Kunchok, Amy , Krecke, Karl N. , Chen, John J. , Caceres, J. , Dominick, Justin, Ferguson, Ian , Kinkel, Revere P., Probasco, John C. , Ruvalcaba, Miguel, Santoro, Jonathan D. , Sieloff, Kurt, Timothy, Jeremy, Weinshenker, Brian G. , Pittock, Sean J, Pittock, Sean J. , Flanagan, E P , Santoro, Jonathan D , Pittock, Sean J , Pittock, S J , Weinshenker, Brian G , Chen, John J , Flanagan, Eoin P. , McKeon, Andrew

Mayo Clinic

Multiple Sclerosis Journal | September 10, 2020 | Volume: 27 | Issue: 8 | Pages: 1175-1186

10.1177/1352458520951046 | PMID 32907470 Get It

Background: The presence of co-existent neuronal antibodies (neuronal-IgG) in patients with myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG1) is not yet well understood. Objectives: The aim of this study was to investigate the co-existence of a broad range of neuronal-IgG in MOG-IgG1+ patients. Methods: MOG-IgG1+ patients were tested for 17 neuronal-IgGs in cerebrospinal fluid (CSF) and serum including NMDA-R-IgG, AMPA-R-IgG, GABAB-R-IgG, LGI1-IgG, CASPR2-IgG, GABAA-R-IgG, GAD65-IgG, mGLUR1-IgG, DPPX-IgG, CRMP5-IgG, amphiphysin-IgG, PCA1,2,Tr, and ANNA1,2,3. Clinical and radiological features of MOG-IgG1+ with NMDA-R-IgG in CSF were compared to a control cohort of MOG-IgG1+ patients without NMDA-R-IgG. Results: A total of 376 MOG-IgG1+ patients underwent testing for neuronal-IgGs. Serum testing for neuronal-IgGs (113 adults, 142 children) identified one child with NMDA-R-IgG (0.7%), one child with CASPR2-IgG (0.7%), one adult with LGI1-IgG (0.9%) and one adult with GABAA-R-IgG (0.9%). CSF testing for neuronal-IgGs (97 adults, 169 children) identified seven children (4%) and seven adults (7%) with NMDA-R-IgG, and one adult with GABAA-R-IgG (1%). The MOG-IgG1+/NMDA-R-IgG+ patients had a median age of 17 (range: 2–39) years. Features associated with MOG-IgG1+/NMDA-R-IgG+ included encephalopathy ( p = 0.001), seizures ( p = 0.045), and leptomeningeal enhancement ( p = 0.045). Conclusion: NMDA-R-IgG was the most frequently detected neuronal-IgG to co-exist with MOG-IgG1. MOG-IgG1+/NMDA-R-IgG+ patients most often presented with encephalopathy and seizures. Testing for MOG-IgG1 and NMDA-R-IgG may be warranted in patients with encephalopathy and inflammatory demyelinating syndromes.